Browsing by Subject "W Medicine and related subjects (NLM Classification)::WL Nervous system"
Now showing items 1-7 of 7
-
BoostCPM trial: image analysis and statistical analysis plan
(The University of Nottingham, 2024-03-12)This document is an image analysis and statistical analysis plan for the BoostCPM trial (brain connectivity-guided optimised theta burst transcranial magnetic stimulation to improve central pain modulation in knee ... -
Employers’ needs when supporting stroke survivors to return to work: A mixed-methods study
(The University of Nottingham, 2024-02-13)The aim of this study was to explore employers’ needs for supporting stroke survivors to return to- and stay in work post-stroke. Study objectives were as follows: 1) To identify and explore factors influencing employers’ ... -
Metabolomics & gene expression microarray data
(The University of Nottingham, 2022-04-22)Metabolomic data (IDEOM file) based on liquid-chromatography mass spectrometry for two brain tumour cell lines (U373 and KNS42), under two cell culture conditions in vitro: lipoprotein-replete (indicated as 'FBS'); ... -
Nigrosome depigmentation as seen on neuromelanin-sensitive MRI at 3T as diagnostic marker in clinical uncertain parkinsonism: analysis plan for the secondary aims of N3iPD study
(The University of Nottingham, 2023-12-01)Access to these files may be requested. Please contact Dr Xing at You.Xing@nottingham.ac.uk. In our prospective multi-centre MRI study at 3T, our primary aim was to establish the prospective diagnostic value of iron-sensitive ... -
Predictors of Relapsing MOGAD: A Scoping Review
(The University of Nottingham, 2024-03-01)Before This scoping review was conducted with the aim of generating an understanding of the current literature about predictors of relapsing myelin oligodendrocyte glycoprotein antibody associated disease (R-MOGAD). The ... -
Protocol - modelling predictors for relapsing disease in MOGAD
(The University of Nottingham, 2023-01-16)In myelin oligodendrocyte glycoprotein antibody associated disease (MOGAD), only approximately 40%-60% of patients develop a relapsing disease course, for which the preventative treatment is long-term immunotherapy. Due ... -
Serial 3T MRI in early Parkinson’s to validate PD progression markers: Rationale and MRI analysis plan for nigral depigmentation at baseline, 6- and 12-months’ follow-up
(The University of Nottingham, 2023-11-02)Access to these files may be requested. Please contact Dr Xing at You.Xing@nottingham.ac.uk. While NM-MRI has shown promise in diagnosing PD, its potential as a progression marker, particularly in the early stages when ...